MARKET WIREReuters • 2h ago
Oil slips more than 1% as talks continue on ending Iran war - ReutersOil slips more than 1% as talks continue on ending Iran war Reuters
Why AORT Stock surged +2.27% Today — RQD Quant Desk Flash
$23.44 +2.27% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $23.49
Artivion Inc. (AORT) carries a Roarable Rating of D+ (Sell) with 54/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D+ • SELL / AVOID
Cap $1.14B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on AORT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is AORT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-01, Artivion Inc. (NYSE: AORT) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $23.44 (+2.27% 1D, market cap $1.14B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 8/20. Across 1016 tracked Health Care issuers, AORT ranks #293 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does AORT compare to PRCT and IRMD in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), AORT carries a Roarable D+ (54/100 RQD), trailing P/E of 117.0x, gross margin of 64.4%, and ROIC of 4.5%. By comparison, PRCT (PROCEPT BioRobotics Corporation) holds a D grade (48/100 RQD, P/E N/A, ROIC -35.0%, cap $1.16B) and IRMD (iRadimed Corporation) posts a C+ grade (68/100 RQD, P/E 48.8x, ROIC 37.7%, cap $1.10B). Among the 5-stock peer group, IRMD leads on earnings multiple (48.8x) while IRMD leads on capital efficiency (37.7% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for AORT?
▼
Per AORT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000784199), Artivion Inc. generated $441.3M in revenue (+13.6% YoY), $9.8M in net income, and $839.0K in free cash flow against $884.8M in total assets and $215.1M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $23.49 (+0.22%)🧬 Disciplined Float (+1.08% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0.2% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY • 51.0% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D+
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk B-
Each axis scored 0–20
12M PRICE TARGET CONE-1.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AORT)Realized 20D OHLCV Swing Band: ±9.4%
Deterministic 5-Pillar Attribution (54/100 Composite)
🔍 WHY AORT SCORES 54/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (28% of score)
FRED Regime × Technicals: 15% of 52W Range • RSI-14 at 46.6 (NEUTRAL RANGE)
▲ #2 Bullish Driver: Whale & Options Positioning+13/20 pts (24% of score)
20D Institutional Volume Accumulation (±9.4% realized swing band)
▼ #1 Drag / Risk Factor: Cash Engine Quality5/20 pts (-15 pt drag)
Capital intensity & 7.6% operating margin leave 15 pts on the table
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$21.26+2.4% Next Q
46
Q2 (-2Q)Grade D$21.78+7% Next Q
49
Q3 (-1Q)Grade C-$23.30+0.6% Next Q
51
CurrentGrade D+$23.44-0.7% Hist 90D α
54
Trajectory: D (46) → D+ (54)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a AORT Turnaround Squeeze
While AORT currently carries a cautious 54/100 (D+) rating due to Cash Engine Quality (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($23.87) and Max Pain ($24.61) forces dealer call-delta covering toward $50.66.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+1.08% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $AORT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “AORT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why AORT Stock surged +2.27% Today — RQD Quant Desk Flash
Artivion Inc. (AORT) surged +2.27% to $23.44, trading at 15% of its 52-week range ($19.16 – $48.25). Stretched risk/reward at 117x P/E (5% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 15% of its 52-week range ($19.16 – $48.25) with RSI-14 at 46.6 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±9.4% around $23.44 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 64.4% gross margin and $839000 annual free cash flow.
Live AORT Headlines & Catalysts
MARKET WIREReuters • 3h ago
Nine people dead in Learjet crash in south Florida, officials say - ReutersNine people dead in Learjet crash in south Florida, officials say Reuters
MARKET WIREReuters • 5h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
MARKET WIRECNBC • 7h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 7h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 8h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 9h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 10h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AORT)
- ✓Walkthrough of AORT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
AORT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -34.58%⚡ TESTING RESISTANCE
2026-10-30O $23.62H $23.62L $21.85C $23.44VOL 627.4K
RES: $23.45SUP: $20.36SMA50: $23.87SMA200: $29.39
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
AORT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
48.0%/yr Implied 5Y Growth
vs. +13.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on AORT today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for AORT. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AORT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AORT)
Health Care Rank #293 of 1016
⚔️ PRCT vs AORT Full Matrix →
1. Head-to-Head Health Care Peer Comparison (AORT vs. PRCT, IRMD, SGP, DRTS)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Artivion Inc. (AORT) ranks #293 by composite RQD confidence (54/100, grade D+) and #344 by equity capitalization ($1.14B). Within this direct 5-issuer industry benchmark cohort, IRMD leads on earnings valuation at 48.8x trailing P/E, while IRMD leads on capital efficiency and profitability with 37.7% ROIC and 76.7% gross margin. IRMD currently holds the highest overall quantitative score in the immediate peer group at 68/100 (C+) compared with AORT at 54/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| AORT
ACTIVE
Artivion Inc. | D+ | 54/100 | 117.0x | 64.4% | 4.5% | +2.27% | $1.14B | Benchmark Subject |
| PRCT PROCEPT BioRobotics Corporation | D | 48/100 | — | 63.7% | -35.0% | +0.50% | $1.16B | /prct-vs-aort → |
| IRMD iRadimed Corporation | C+ | 68/100 | 48.8x | 76.7% | 37.7% | +2.16% | $1.10B | /irmd-vs-aort → |
| SGP SpyGlass Pharma Inc. | D- | 41/100 | — | — | -35.0% | -1.06% | $1.09B | /sgp-vs-aort → |
| DRTS Alpha Tau Medical Ltd. | E | 33/100 | — | — | -35.0% | -0.90% | $1.22B | /drts-vs-aort → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000784199In its most recent audited fiscal period (FY2025, filed 2025-12-31), Artivion Inc. (AORT) reported GAAP revenue of $441.3M (+13.6% vs. FY2024 revenue of $388.5M , and +24.7% cumulative change since FY2023) , GAAP net income of $9.8M, operating cash flow of $39.9M, and free cash flow of $839.0K (-92.4% YoY). On the balance sheet, AORT closed FY2025 with $884.8M in total assets against $215.1M in total debt (Altman Z-Score: 2.46, Piotroski F-Score: 9/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $441.3M | $9.8M | $39.9M | $839.0K | $884.8M | $215.1M |
| FY2024 (FY) | 2024-12-31 | $388.5M | -$13.4M | $22.2M | $11.0M | $789.1M | $314.2M |
| FY2023 (FY) | 2023-12-31 | $354.0M | -$30.7M | $18.8M | $18.8M | — | — |
3. AORT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs AORT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Artivion Inc. (NYSE: AORT) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $23.44 (+2.27% 1D, market cap $1.14B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 8/20. Across 1016 tracked Health Care issuers, AORT ranks #293 in composite RQD confidence.
How does AORT compare to PRCT and IRMD in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), AORT carries a Roarable D+ (54/100 RQD), trailing P/E of 117.0x, gross margin of 64.4%, and ROIC of 4.5%. By comparison, PRCT (PROCEPT BioRobotics Corporation) holds a D grade (48/100 RQD, P/E N/A, ROIC -35.0%, cap $1.16B) and IRMD (iRadimed Corporation) posts a C+ grade (68/100 RQD, P/E 48.8x, ROIC 37.7%, cap $1.10B). Among the 5-stock peer group, IRMD leads on earnings multiple (48.8x) while IRMD leads on capital efficiency (37.7% ROIC).
What are the biggest fundamental strengths and SEC risk factors for AORT?
Per AORT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000784199), Artivion Inc. generated $441.3M in revenue (+13.6% YoY), $9.8M in net income, and $839.0K in free cash flow against $884.8M in total assets and $215.1M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is AORT trading relative to its 50-day, 200-day, and 52-week technical levels?
AORT last traded at $23.44 (+2.27% on volume of 418,218 shares), positioning the stock -1.80% below its 50-day simple moving average ($23.87) and -20.24% below its 200-day simple moving average ($29.39). Across its 52-week range of $19.16 to $48.25, AORT sits at the 14.7% percentile with a 14-day RSI of 46.6 (NEUTRAL RANGE) and an implied next-earnings move of ±9.4% ($21.24 to $25.64).
AORT Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is AORT stock moving today?
Why AORT Stock surged +2.27% Today — RQD Quant Desk Flash. Stretched risk/reward at 117x P/E (5% return on capital) under elevated 10-year interest-rate pressure.